Hematologic safety of 177Lu-PSMA-617 radioligand therapy in patients with metastatic castration-resistant prostate cancer
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
Online-Ressource
- Language
-
Englisch
- Bibliographic citation
-
In: EJNMMI Research 11.2021, art. 61, doi:10.1186/s13550-021-00805-7, ISSN 2191-219X
- Event
-
Veröffentlichung
- (where)
-
Frankfurt am Main
- (who)
-
Universitätsbibliothek Johann Christian Senckenberg
- (when)
-
2021
- Creator
-
Gröner, Daniel
Nguyen, Cam Tu
Baumgarten, Justus
Bockisch, Benjamin
Davis, Karen
Happel, Christian
Mader, Nicolai
Nguyen Ngoc, Christina
Wichert, Jennifer
Banek, Séverine
Mandel, Philipp
Chun, Felix
Tselis, Nikolaos
Grünwald, Frank
Sabet, Amir
- URN
-
urn:nbn:de:hebis:30:3-635902
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
25.03.2025, 1:42 PM CET
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Gröner, Daniel
- Nguyen, Cam Tu
- Baumgarten, Justus
- Bockisch, Benjamin
- Davis, Karen
- Happel, Christian
- Mader, Nicolai
- Nguyen Ngoc, Christina
- Wichert, Jennifer
- Banek, Séverine
- Mandel, Philipp
- Chun, Felix
- Tselis, Nikolaos
- Grünwald, Frank
- Sabet, Amir
- Universitätsbibliothek Johann Christian Senckenberg
Time of origin
- 2021
Other Objects (12)
Hämatologische Sicherheit der 177Lu-PSMA-617 Radioligandentherapie bei Patienten mit metastasiertem kastrationsresistentem Prostatakarzinom
Salvage radioligand therapy with repeated cycles of 177Lu-PSMA-617 in metastatic castration-resistant prostate cancer with diffuse bone marrow involvement
Prostate cancer: active surveillance, diagnostic modalities and biopsy in the management of prostate cancer
Molecular analysis of circulating tumor cells of metastatic castration-resistant Prostate Cancer Patients receiving 177Lu-PSMA-617 Radioligand Therapy
Outcome of 177Lu-PSMA-617 radioligand therapy in chemo-refractory patients with metastatic castration-resistant early-onset prostate cancer
Evaluation eines Clinical Decision Support System zur Unterstützung eines möglichst evidenzbasierten perioperativen Managements von antikoagulierten Patienten
Retrospektive Analyse des Outcomes von Patienten nach Ileostomarückverlagerung in Abhängigkeit vom Ausbildungsstand des Operateurs
Improved therapeutic index with the novel PSMA-ligand 177Lu-rhPSMA-10.1 compared to 177Lu-PSMA I&T - an intrapatient comparison [Abstract]
Joint EANM/SNMMI procedure guideline for the use of 177Lu-labeled PSMA-targeted radioligand-therapy (177Lu-PSMA-RLT)
Impact of time to castration resistance on survival in metastatic hormone sensitive prostate cancer patients in the era of combination therapies
Long-term nephrotoxicity of 177Lu-PSMA radioligand therapy
177Lu-rhPSMA-10.1 induces tumor response in a patient with mCRPC after PSMA-directed radioligand therapy with 177Lu-PSMA-I AND T
Hämatologische Sicherheit der 177Lu-PSMA-617 Radioligandentherapie bei Patienten mit metastasiertem kastrationsresistentem Prostatakarzinom
Salvage radioligand therapy with repeated cycles of 177Lu-PSMA-617 in metastatic castration-resistant prostate cancer with diffuse bone marrow involvement
Prostate cancer: active surveillance, diagnostic modalities and biopsy in the management of prostate cancer
Molecular analysis of circulating tumor cells of metastatic castration-resistant Prostate Cancer Patients receiving 177Lu-PSMA-617 Radioligand Therapy
Outcome of 177Lu-PSMA-617 radioligand therapy in chemo-refractory patients with metastatic castration-resistant early-onset prostate cancer
Evaluation eines Clinical Decision Support System zur Unterstützung eines möglichst evidenzbasierten perioperativen Managements von antikoagulierten Patienten
Retrospektive Analyse des Outcomes von Patienten nach Ileostomarückverlagerung in Abhängigkeit vom Ausbildungsstand des Operateurs
Improved therapeutic index with the novel PSMA-ligand 177Lu-rhPSMA-10.1 compared to 177Lu-PSMA I&T - an intrapatient comparison [Abstract]
Joint EANM/SNMMI procedure guideline for the use of 177Lu-labeled PSMA-targeted radioligand-therapy (177Lu-PSMA-RLT)
Impact of time to castration resistance on survival in metastatic hormone sensitive prostate cancer patients in the era of combination therapies
Long-term nephrotoxicity of 177Lu-PSMA radioligand therapy
177Lu-rhPSMA-10.1 induces tumor response in a patient with mCRPC after PSMA-directed radioligand therapy with 177Lu-PSMA-I AND T
Hämatologische Sicherheit der 177Lu-PSMA-617 Radioligandentherapie bei Patienten mit metastasiertem kastrationsresistentem Prostatakarzinom
Salvage radioligand therapy with repeated cycles of 177Lu-PSMA-617 in metastatic castration-resistant prostate cancer with diffuse bone marrow involvement
Prostate cancer: active surveillance, diagnostic modalities and biopsy in the management of prostate cancer
Molecular analysis of circulating tumor cells of metastatic castration-resistant Prostate Cancer Patients receiving 177Lu-PSMA-617 Radioligand Therapy
Outcome of 177Lu-PSMA-617 radioligand therapy in chemo-refractory patients with metastatic castration-resistant early-onset prostate cancer
Evaluation eines Clinical Decision Support System zur Unterstützung eines möglichst evidenzbasierten perioperativen Managements von antikoagulierten Patienten
Retrospektive Analyse des Outcomes von Patienten nach Ileostomarückverlagerung in Abhängigkeit vom Ausbildungsstand des Operateurs
Improved therapeutic index with the novel PSMA-ligand 177Lu-rhPSMA-10.1 compared to 177Lu-PSMA I&T - an intrapatient comparison [Abstract]
Joint EANM/SNMMI procedure guideline for the use of 177Lu-labeled PSMA-targeted radioligand-therapy (177Lu-PSMA-RLT)
Impact of time to castration resistance on survival in metastatic hormone sensitive prostate cancer patients in the era of combination therapies
Long-term nephrotoxicity of 177Lu-PSMA radioligand therapy